X0306 4 2016-09-01 1 0001416792 Relypsa Inc RLYP 0001219023 MCGIRR DAVID W J C/O RELYPSA, INC. 100 CARDINAL WAY REDWOOD CITY CA 94063 1 0 0 0 Common Stock 2016-09-01 4 U 0 2729 32.00 D 2250 D Common Stock 2016-09-01 4 D 0 2250 32.00 D 0 D Stock Option (Right to Buy) 3.96 2016-09-01 4 D 0 55232 D 2022-11-20 Common Stock 55232 0 D Stock Option (Right to Buy) 7.40 2016-09-01 4 D 0 10140 D 2023-07-23 Common Stock 10140 0 D Stock Option (Right to Buy) 23.96 2016-09-01 4 D 0 3828 D 2024-06-18 Common Stock 3828 0 D Stock Option (Right to Buy) 35.79 2016-09-01 4 D 0 4500 D 2025-06-03 Common Stock 4500 0 D Stock Option (Right to Buy) 17.00 2016-09-01 4 D 0 4500 D 2026-06-20 Common Stock 4500 0 D Pursuant to the terms of the Agreement and Plan of Merger, dated as of July 20, 2016 (the "Merger Agreement"), by and among the Issuer, Galencia AG, a public limited company existing under the laws of Switzerland ("Parent"), and Vifor Pharma USA Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent, on September 1, 2016, shares disposed of in exchange for cash consideration of $32.00 per share, without interest, subject to any applicable withholding taxes. Pursuant to the terms of the Merger Agreement, on September 1, 2016, each award of restricted stock units and stock options was cancelled in exchange for the right to receive $32.00 per share in cash less any applicable withholding taxes and in the case of stock options, less the applicable exercise price. Pursuant to the terms of the Merger Agreement, on September 1, 2016, the stock option was cancelled and no cash payment was made as the exercise price exceeded $32.00 per share. /s/ Ronald A. Krasnow, as Attorney-in-Fact for David W.J. McGirr 2016-09-02